NewAmsterdam Pharma Company (NAMS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on February 27. Analyst Roanna Ruiz from Leerink Partners maintained a Buy rating on the stock and has a $46.00 price target.
Roanna Ruiz has given her Buy rating due to a combination of factors that highlight NewAmsterdam Pharma Company’s potential for growth and innovation. The company’s lead product, obicetrapib, is seen as a potentially groundbreaking oral therapy for cardiovascular disease, offering a unique efficacy and safety profile that addresses unmet needs in LDL-C management. Recent Phase 3 trials, BROADWAY and TANDEM, have shown significant efficacy in reducing LDL-C levels with a safety profile comparable to a placebo, reinforcing confidence in its commercial prospects.
Moreover, NewAmsterdam’s strong financial position, with a reported cash reserve of $834.2 million, is expected to support operations through key clinical milestones, including the PREVAIL CV outcomes trial. The anticipated EMA submission by partner Menarini and future data releases are seen as catalysts that could further differentiate obicetrapib and strengthen investor confidence. These elements, combined with management’s strategic plans for additional trials and detailed data presentations, underpin Ruiz’s optimistic outlook for the company’s stock.
In another report released on February 27, Scotiabank also maintained a Buy rating on the stock with a $52.00 price target.
NAMS’s price has also changed moderately for the past six months – from $16.770 to $20.910, which is a 24.69% increase.
Questions or Comments about the article? Write to editor@tipranks.com